Aura Biosciences, Inc. (AURA) NASDAQ
8.02
+0.09(+1.13%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.02
+0.09(+1.13%)
Currency In USD
| Previous Close | 7.93 |
| Open | 7.97 |
| Day High | 8.09 |
| Day Low | 7.7 |
| 52-Week High | 9.54 |
| 52-Week Low | 4.35 |
| Volume | 616,370 |
| Average Volume | 433,845 |
| Market Cap | 514.88M |
| PE | -4.69 |
| EPS | -1.71 |
| Moving Average 50 Days | 6.85 |
| Moving Average 200 Days | 6.2 |
| Change | 0.09 |
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 9:05 PM GMT
BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos,
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 11:00 AM GMT
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
GlobeNewswire Inc.
May 15, 2025 1:32 PM GMT
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an u